World Wide Search | World Class Leaders

US Partner of IMD International Search

C h i e f S c i e n t i f i c O f f i c e r Search & Selection

2014

TOGETHER, WE CAN MAKE A DIFFERENCE

US Partner of IMD International Search

Founded in 2010, TESARO is a

publicly-held, oncology-focused

biopharmaceutical company

dedicated to improving the lives of

cancer patients by leveraging the

experience and competencies of its

leadership team to acquire, develop

and commercialize safer and more

effective therapies for the treatment

and support of patients with cancer.

World Wide Search | World Class Leaders

US Partner of IMD International Search

ESARO has achieved numerous milestones since its founding in 2010 and is, after successful Phase III trials, on the threshold of submitting an NDA in mid-2014 for rolapitant, a potent and selective neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).

nrollment is ongoing in two Phase 3 trials of niraparib, a potentially best in class, orally active PARP inhibitor, in ovarian cancer maintenance and BRCA-positive breast cancer. Together, these initial two market opportunities are estimated to exceed $3B worldwide.

dditionally, TESARO recently announced the expansion of the niraparib development program to include further trials in small cell lung cancer and first line ovarian cancer maintenance.

ost recently, TESARO announced an exclusive worldwide license agreement with AnaptysBio for multiple immuno-oncology programs, which provides a portfolio of candidates focused on high value targets, potentially augments the value of other pipeline candidates, and enhances TESARO's overall oncology strategy. The therapeutic antibodies selected from these programs will form the basis of a strategic platform that will enable TESARO to develop novel monotherapy and combination-based approaches with immuno-oncology and other anti-cancer agents in a variety of indications.

Near-Term Milestones: Nearing NDA submission of rolapitant for the prevention of CINV; Continuing PH III clinical development and successfully commercialize

niraparib for cancers that are susceptible to PARP inhibition; Advancing TSR-011 through clinical trials for treatment of NSCLC and other

tumor types associated with ALK and TRK mutations; Potential first-in-class anti-TIM-3 antibody clinical candidate expected to be

selected second-quarter 2014; Anti-LAG-3 antibody clinical candidate expected to be selected by third-

quarter 2014; Dual reactive antibody clinical candidates targeting PD-1/TIM-3 and PD-

1/LAG-3 expected to be selected by first-quarter 2015; Investigation planned - preclinical combinations of TSR-042 (anti-PD-1

antibody) with each of TSR-011 (ALK/TRK inhibitor) and niraparib (PARP inhibitor);

First clinical trial of TSR-042 projected to begin in H2 2015.

See TESARO’s ASCO 2014 Presentation

US Partner of IMD International Search

Executing on the Mission of Improving the Lives of Patients with Cancer

Phase 3 Trials of Rolapitant Initiated

2010 2011 2012 2013 2014

TSR-011 IND Cleared

TSR-011 Phase 1 Trial

Initiated

Niraparib In-Licensed

Initial Phase 1 TSR-011 Data

Presented

Niraparib Phase 3 Trial in Ovarian Cancer Initiated

Rolapitant IV Clinical Program

Initiated

First Two Pivotal Trials of Rolapitant Successfully

Completed

IO Platform

In-Licensed

Third Pivotal Trial of Rolapitant Successfully

Completed

Niraparib Phase 3 Trial in Breast Cancer Initiated

Market Cap - $1 Billion

Rolapitant In-Licensed

TSR-011 In-Licensed

Series B Financing - $101M IPO - $87M

Follow-on Stock Offering -

$98M

TESARO Founded; Series A Financing -

$20M

Follow-on Stock Offering -

$101M

World Wide Search | World Class Leaders

US Partner of IMD International Search

Opportunity

ESARO is undergoing a full-scale expansion in preparation of product commercialization post-FDA approvals, and to support the expansion of their exciting immuno-oncology platform.

o-Founders, Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President & CSO, are building a world-class team dedicated to improving the lives of patients with cancer and leveraging their collective knowledge and experience to transform TESARO into an integrated development and commercial stage company. With a current market capitalization of ~$1Billion, and a successful track record in fund-raising, the company is well-positioned to capitalize on its impressive and balanced portfolio of products under development.

ith this foundation, impressive history of accomplishments and trajectory in just four years since inception, a seasoned management team, and strong and growing pipeline of oncology and immuno-oncology candidates, TESARO is executing on its mission to successfully commercialize multiple products globally, and fulfill its vision of re-defining cancer treatment, including immuno-oncology as a platform that will become the foundation of many future cancer therapy regimens.

his rapid growth demands that TESARO expand their management team by acquiring a best-in-class Chief Scientific Officer, allowing Mary Lynne Hedley to focus on her role as President of the organization.

his is a unique opportunity to join an exciting biotech company that 1) is well-funded to pursue a very robust pipeline of candidates under various stages of development; 2) is led by a senior leadership team that is highly regarded among the investor community; 3) maintains a collegial and family-style culture while operating in an intense, high-pressure/high-impact environment; and 4) has the true promise of bringing to reality safer and more effective therapeutics and changing the lives of patients with cancer

Meet the TESARO Co-Founders!

US Partner of IMD International Search

Scope of Accountabilities he Chief Scientific Officer will report directly to the President, be an integral member of the senior

executive team, and provide the highest level of scientific knowledge and direction with a strategic focus on leveraging assets and driving products towards commercialization across the portfolio. This individual will work collaboratively with all executive team members in driving the future vision for TESARO, enhancing its value proposition and defining its strategic rationale and roadmap to delivery of organizational growth, profitability, and sustainability.

ith an emphasis on being a champion of the organization, s/he will seek out partnerships and alliance targets in the field of modern immuno-oncology therapies and related science to recognize the value of TESARO’s portfolio of the most promising novel oncology and supportive care product candidates worldwide.

ith touch points across the entire organization, s/he will develop a strategic framework that enables the organization to evaluate internal and external growth opportunities that leverage TESARO’s current and future assets, knowledge and core competencies to flourish as an innovative and fast-growth organization and reinforce its commitment in cancer patients.

Specific Accountabilities include:

Lead all scientific efforts of the company towards advancing drug candidates for the treatment of cancer patients;

Collaborate across the scientific leadership team to establish the company’s strategic research and development roadmap and activities in support of the portfolio strategy;

Lead the interface with clinical development to ensure appropriate preclinical development and assessment of each drug candidate for the identified clinical indication;

Identify and support necessary IND enabling studies in line with corporate and project team objectives;

Generate, develop and implement nonclinical research and biomarker research and development plans;

Build the value of the existing portfolio by identifying and establishing partnerships to explore combination approaches to the development of cancer therapeutics, with a particular focus on the immunotherapy platform, while also identifying new potential indications for existing pipeline candidates;

Develop a deep scientific understanding of immuno-oncology at TESARO; recommend and promote prudent development efforts including potential combination approaches for immunotherapy platform;

Establish and manage relationships with TESARO’s Scientific Advisors, external KOL’s and experts in immunology and oncology throughout academia and industry;

World Wide Search | World Class Leaders

US Partner of IMD International Search

Recommend potential new targets for in-license via interactions with academic researchers and sourcing via literature, congresses, and relationships; deliver key scientific diligence of these and other potential candidates for in-licensing;

Motivate associates through a time of rapid change and growth, drive a positive organizational culture, and provide ongoing coaching, guidance and feedback to ensure functional excellence and success;

Liaise across functions, as appropriate, and build effective cross-functional communications to ensure strategies are aligned with the corporate strategy, goals and project milestones;

Provide insight to the President, CEO and Board by developing strong credibility as a scientific expert and leader, as well as demonstrating of deep understanding of the industry and associated business landscape, and thereby delivering solid foundational context for critical strategic direction;

Be an outward champion of the organization and its mission, expanding TESARO’s influence throughout the industry, strengthening its reputation for excellence in innovative science and practical therapies for the treatment of cancer.

Key Year One Objectives Gain understanding of current programs, key assumptions, deliverables, internal

and external risks and deliver a fully vetted R/Preclinical roadmap/goals/plans for current pipeline that integrates with current development goals;

Develop organizational buy-in for a vision related to sphere of influence, conduct a gap analysis related to vision, implement necessary changes, and hire key staff.

Define immuno-oncology strategy that creates a competitive niche and is operationally actionable for TESARO;

Define and implement biomarker strategy/timeline/budget for niraparib that syncs with the overall development plan, including an FDA agreed path forward for assessing samples in NOVA study as well as extension to other clinical indications, i.e., first line ovarian/SCLC;

Identify opportunities for PD-1 combinations/development and support with non-clinical data, Phase 1 clinical plan, partnerships proposed, biomarker assessment plan in place for early studies;

Define and implement a strategic roadmap for nonclinical activities that fully support corporate and long term development goals, including enabling full value recognition for current assets.

US Partner of IMD International Search

Desired Qualifications he Chief Scientific Officer will bring a deep understanding of the Biotechnology industry,

immunology, oncology and emerging immuno-oncology platforms, know the key industry players including the leading research institutions, and have an understanding of the multi-dimensions of a complex organization in the drug development and commercialization arena.

Professional qualifications will include:

A Ph.D., preferably in immunology, is required; a strong foundation of knowledge of the science of modern immuno-therapies; recognized as an expert in the area of immunology;

20+ years experience in the Pharmaceutical, Biopharma, or Biotechnology industry, to include several years as a scientific leader of oncology and immunology products that realized demonstrated success;

Understanding of challenges and issues associated with biomarker research and development;

Experience in the development of drug candidates from research through preclinical development and a proven record for advancing drug candidates into the clinic; knowledge of FDA, EMEA, and ICH guidelines governing nonclinical development;

Deep knowledge of leading Research & Development institutions as well as KOL’s worldwide in the area of immunology, oncology and combination therapies and related technologies;

Superior conceptual and critical thinking skills, naturally innovative, and ability to integrate disparate input with demonstrated intellectual rigor is an absolute must;

Significant experience and knowledge of the commercial side of the business, as well as strategic planning and resource management in a fast-paced, challenging environment;

Ability to structure, manage, and coordinate complex cross-enterprise projects, analyses and processes with multiple work streams and multiple stakeholders at both senior and junior levels;

An excellent and persuasive communicator with strong oral and flawless written communication skills.

Personal characteristics and attributes will include:

Particularly energetic, responding with quick a sense of urgency; an outcome focused individual who sets genuinely ambitious, challenging goals, in a results-oriented organization;

Interpersonal skills to include a sense of humility, tactful diplomacy, and ability to influence; the gravitas, self-awareness and leadership to operate at the highest intellectual and strategic levels;

Ability to operate effectively in environments with rapid change, complexity and uncertainty;

A team-player with a collaborative approach and a natural desire to achieve consensus; a strong relationship builder;

A value system that includes flawless personal and business honesty, integrity, openness, and a dedication to exceeding expectations.

World Wide Search | World Class Leaders

US Partner of IMD International Search

Location The position is based in the Boston, MA area and will include moderate travel.

Compensation The successful candidate will receive a competitive and compelling compensation package, which will include an attractive base salary, performance based bonus, equity participation, and long-term incentives.

Application Process Candidates who represent the opportunities and attributes presented in this profile are encouraged to contact Epsen Fuller Group. All inquires are kept strictly confidential and may be made to: Equal Employment Opportunity Epsen Fuller Group shall provide equal employment opportunity to all qualified candidates, and will refer candidates without regard to race, color, religion, national origin, sex, age, disability, veteran status or any other legally protected basis. Epsen Fuller Group shall comply with all applicable laws, rules and regulations in the performance of duties pursuant to this project, including but not limited to, Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, the Americans with Disabilities Act, and state and local anti-discrimination laws to the extent applicable.

Thomas Fuller CEO & Managing Partner tfuller@EpsenFuller.com

+1 212-392-4842

Rick Cannellos Life Science Partner

rcannellos@EpsenFuller.com +1 646-706-7602

Elisabeth Parkinson Director, Life Science Research eparkinson@EpsenFuller.com

+1 443-996-8663

Executive & Board Director Search | Management Assessment

Leadership & Team Development | M&A and Board Advisory

N e w Y o r k | N e w J e r s e y | S a n F r a n c i s c o

Building Talent Driven Organizations